Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Tools & Technology › PCR › HeiScreen Preps Liquid Biopsy Breast Cancer Test for Year-End Launch

HeiScreen Preps Liquid Biopsy Breast Cancer Test for Year-End Launch

Mar 12, 2019
|
Justin Petrone
Premium

NEW YORK (GenomeWeb) — HeiScreen, a German molecular diagnostics company, is moving ahead with plans to introduce a liquid biopsy-based test for breast cancer detection for clinical use by the end of the year.

The company's assay relies on a set of 15 methylation and microRNA markers to determine whether a woman has breast cancer. HeiScreen is in the process of obtaining CE-IVD marking for the test with the aim of making it available to German clinicians later in 2019.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Feb
23
Featured Webinar

After the Surge: Driving Sample Processing Efficiency of Coronavirus Samples

Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Featured Webinar

Case Study: Rapid Development and Manufacturing Scaleup of a Point-of-Care COVID-19 Test

Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

What's Popular?

In PCR

  1. CDC Study Finds Abbott BinaxNow SARS-CoV-2 Antigen Test Less Sensitive Than PCR, But Still Useful

  2. Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

  3. Lucira Health Files for $115M IPO

  4. Bio-Rad, United Biomedical Get FDA Emergency Use Authorizations for Coronavirus Tests

  5. Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.